CHARLESTON, S.C.--(BUSINESS WIRE)--Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”) today announced that Chairman, President and Chief Executive Officer David A. Dodd will participate in the 18th Annual BIO CEO & Investor Conference, on February 8 & 9, 2016 in New York City. Mr. Dodd will update participants on the status of the Company’s two Phase 3 clinical trials and will continue the Company’s efforts to secure additional partners for the development of Zoptrex™, which if approved by the FDA, would be the first systemic therapy for the treatment of advanced and recurrent endometrial cancer, and for Macrilen™, which if approved by the FDA, would be the first orally administered drug indicated for the evaluation of adult growth hormone deficiency (“AGHD”).
